𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Homocysteine and cognitive impairment in Parkinson's disease: A biochemical, neuroimaging, and genetic study

✍ Scribed by Maria C. Rodriguez-Oroz; Pablo Martínez Lage; Jose Sanchez-Mut; Isabel Lamet; Javier Pagonabarraga; Jon B. Toledo; David García-Garcia; Pedro Clavero; Lluis Samaranch; Cecilia Irurzun; Juan M. Matsubara; Jaione Irigoien; Emilia Bescos; Jaime Kulisevsky; Jordi Pérez-Tur; Jose A. Obeso

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
141 KB
Volume
24
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The role of the plasma level of homocysteine (Hcy), as a primary outcome, and the effect of silent cerebrovascular lesions and genetic variants related to Hcy metabolism, as secondary outcomes, in the cognitive decline and dementia in Parkinson's disease (PD) were studied. This case–control study focused on 89 PD patients of minimum 10 years of evolution and older than 60 years, who were neuropsychologically classified either as cognitively normal (n = 37), having mild cognitive impairment (Petersen criteria) (n = 22), or suffering from dementia (DSM‐IV) (n = 30), compared with cognitively normal age‐matched control subjects (n = 30). Plasma levels of Hcy, vitamins B12 and B6, folic acid, polymorphisms in genes related to Hcy metabolism (MTHFR, MTR, MTRR, and CBS) and silent cerebrovascular events were analyzed. Plasma levels of Hcy were increased in PD patients (P = 0.0001). There were no differences between the groups of patients. The brain vascular burden was similar among PD groups. There was no association between polymorphisms in the studied genes and the Hcy plasma levels or cognitive status in PD patients. We found no evidence for a direct relationship between Hcy plasma levels and cognitive impairment and dementia in PD. No indirect effect through cerebrovascular disease or genetic background was found either. © 2009 Movement Disorder Society

📜 SIMILAR VOLUMES

MRI and cognitive impairment in Parkinso
MRI and cognitive impairment in Parkinson's disease
✍ Naroa Ibarretxe-Bilbao; Eduardo Tolosa; Carme Junque; Maria-Jose Marti 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 1 views

## Abstract Patients with Parkinson's disease (PD) may present impairment in cognitive functions even at early stages of the disease. When compared with the general population, their risk of dementia is five to six times higher. Recent investigations using structural MRI have shown that dementia in

Cognitive impairment and dementia in Par
Cognitive impairment and dementia in Parkinson's disease
✍ Karen Marder 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 1 views

## Abstract Over the last decade, the importance of cognitive impairment and dementia in Parkinson's disease (PDD) has been increasingly recognized. Investigators have proposed criteria for PD dementia, and mild cognitive impairment. Risk profiles associated with the development of dementia based o

Controlled study of decision-making and
Controlled study of decision-making and cognitive impairment in Parkinson's disease
✍ Javier Pagonabarraga; Carmen García-Sánchez; Gisela Llebaria; Berta Pascual-Seda 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 1 views

## Abstract Impulse control disorders (ICD) related to reward‐processing dysfunction have been reported in Parkinson's disease (PD). The relationship between clinical markers of limbic dysfunction with demographic variables and cognitive status of PD is incompletely known. Our objective was to furt

Cognitive and functional neuroimaging co
Cognitive and functional neuroimaging correlate for anosognosia in Mild Cognitive Impairment and Alzheimer's disease
✍ Asmus Vogel; Steen G. Hasselbalch; Anders Gade; Morten Ziebell; Gunhild Waldemar 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 1 views

## Abstract ## Objectives To investigate the correlation between anosognosia and behavioural symptoms, performance on executive tests, and frontal cortex regional cerebral blood flow (rCBF) in patients with ‘amnestic mild cognitive impairment’ (MCI) and mild Alzheimer's disease (AD). ## Methods

Cognitive impairment in nondemented Park
Cognitive impairment in nondemented Parkinson's disease
✍ Paolo Barone; Dag Aarsland; David Burn; Murat Emre; Jaime Kulisevsky; Daniel Wei 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB 👁 1 views

## Abstract A substantial percentage of patients with newly diagnosed Parkinson's disease without dementia are reported to be affected by cognitive impairment (CI). In practice, however, CI is underrecognized, as the signs may not be apparent in early‐stage disease and many routine assessment tools

Amnestic mild cognitive impairment in Pa
Amnestic mild cognitive impairment in Parkinson's disease: A brain perfusion SPECT study
✍ Flavio Nobili; Giovanni Abbruzzese; Silvia Morbelli; Roberta Marchese; Nicola Gi 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB

## Abstract The purpose of this study was to investigate cortical dysfunction in Parkinson's disease (PD) patients with amnestic deficit (PD‐MCI). Perfusion single photon emission computed tomography was performed in 15 PD‐MCI patients and compared (statistical parametric mapping [SPM2]) with three